Evaluation of a commercially available Zika virus IgM ELISA: specificity in focus

Kamran Kadkhoda; Ainsley Gretchen; Adrianna Racano

doi:10.1016/j.diagmicrobio.2017.04.002

Evaluation of a commercially available Zika virus IgM ELISA: specificity in focus

Diagn Microbiol Infect Dis. 2017 Jul;88(3):233-235. doi: 10.1016/j.diagmicrobio.2017.04.002. Epub 2017 Apr 7.

Authors

Kamran Kadkhoda¹, Ainsley Gretchen², Adrianna Racano²

Affiliations

¹ Cadham Provincial Public Health Laboratory, Winnipeg, MB, Canada; Departments of Medical Microbiology & Infectious Diseases, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada; Department of Immunology, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada. Electronic address: kamran.kadkhoda@gov.mb.ca.
² Cadham Provincial Public Health Laboratory, Winnipeg, MB, Canada.

PMID: 28478111
DOI: 10.1016/j.diagmicrobio.2017.04.002

Abstract

Zika virus (ZIKV), an emerging arbovirus, has become the center of attention since it was linked to congenital abnormalities. Given the overlapping clinical picture of ZIKV disease with other infectious diseases and as an exigent public health matter, timely and reliable diagnosis of ZIKV infection is crucial. We evaluated the performance of a commercially available NS1-based ZIKV IgM ELISA. Our results showed suboptimal sensitivity within the first 5 days after onset while specificity remained robust.

Keywords: Elisa; IgM; Specificity; Zika.

Publication types

Evaluation Study

MeSH terms

Antibodies, Viral / blood*
Enzyme-Linked Immunosorbent Assay / methods*
Humans
Immunoglobulin M / blood*
Immunologic Factors
Sensitivity and Specificity
Serologic Tests / methods*
Zika Virus / immunology*
Zika Virus Infection / diagnosis*

Substances

Antibodies, Viral
Immunoglobulin M
Immunologic Factors